PE20081556A1 - Formas cristalinas de glyt1 - Google Patents
Formas cristalinas de glyt1Info
- Publication number
- PE20081556A1 PE20081556A1 PE2008000055A PE2008000055A PE20081556A1 PE 20081556 A1 PE20081556 A1 PE 20081556A1 PE 2008000055 A PE2008000055 A PE 2008000055A PE 2008000055 A PE2008000055 A PE 2008000055A PE 20081556 A1 PE20081556 A1 PE 20081556A1
- Authority
- PE
- Peru
- Prior art keywords
- glyt1
- pain
- referred
- crystal shapes
- peaks
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 abstract 2
- -1 (S) -2,2 , 2-TRIFLUOR-1-METHYL-ETHOXY Chemical class 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06127269 | 2006-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081556A1 true PE20081556A1 (es) | 2008-11-28 |
Family
ID=38988312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000055A PE20081556A1 (es) | 2006-12-28 | 2008-01-02 | Formas cristalinas de glyt1 |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US20080214561A1 (https=) |
| EP (1) | EP2114405B1 (https=) |
| JP (1) | JP4799666B2 (https=) |
| KR (1) | KR101130146B1 (https=) |
| CN (1) | CN101573114A (https=) |
| AR (1) | AR064545A1 (https=) |
| AU (1) | AU2007341356B2 (https=) |
| BR (1) | BRPI0720829B8 (https=) |
| CA (1) | CA2673667A1 (https=) |
| CL (1) | CL2007003830A1 (https=) |
| CO (1) | CO6190613A2 (https=) |
| CR (1) | CR10846A (https=) |
| CY (1) | CY1116350T1 (https=) |
| DK (1) | DK2114405T3 (https=) |
| EC (1) | ECSP099471A (https=) |
| ES (1) | ES2535040T3 (https=) |
| HR (1) | HRP20150573T1 (https=) |
| HU (1) | HUE025032T2 (https=) |
| MA (1) | MA31029B1 (https=) |
| MX (1) | MX2009006859A (https=) |
| MY (1) | MY188367A (https=) |
| NO (1) | NO342150B1 (https=) |
| NZ (1) | NZ577502A (https=) |
| PE (1) | PE20081556A1 (https=) |
| PL (1) | PL2114405T3 (https=) |
| PT (1) | PT2114405E (https=) |
| RS (1) | RS53910B1 (https=) |
| RU (1) | RU2463295C2 (https=) |
| SI (1) | SI2114405T1 (https=) |
| TW (1) | TWI388552B (https=) |
| UA (1) | UA100232C2 (https=) |
| WO (1) | WO2008080821A1 (https=) |
| ZA (1) | ZA200904423B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009006859A (es) | 2006-12-28 | 2009-07-03 | Hoffmann La Roche | Formas cristalinas de glyt1. |
| JP6074142B2 (ja) * | 2009-02-26 | 2017-02-01 | タール ファーマシューティカルズ，インコーポレイテッド | 医薬化合物の結晶化 |
| KR101196354B1 (ko) * | 2010-09-03 | 2012-11-01 | 서유헌 | 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 |
| CN104334550A (zh) * | 2012-05-25 | 2015-02-04 | 巴斯夫欧洲公司 | 1,5-二甲基-6-硫代-3-(2,2,7-三氟-3-氧代-4-(丙-2-炔基)-3,4-二氢-2H-苯并[b][1,4]噁嗪-6-基)-1,3,5-三嗪烷-2,4-二酮的晶型B |
| US8927412B1 (en) * | 2013-08-01 | 2015-01-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Multi-chip package and method of formation |
| MX354615B (es) * | 2013-10-02 | 2018-03-08 | Centro De Investig Y De Estudios Avanzados Del I P N | Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus. |
| KR20220125326A (ko) | 2020-01-09 | 2022-09-14 | 디스크 메디슨, 인크. | 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법 |
| JP7096956B2 (ja) * | 2020-07-13 | 2022-07-06 | 日本碍子株式会社 | 精製方法 |
| EP4337199A4 (en) * | 2021-05-14 | 2025-03-19 | Disc Medicine, Inc. | Methods for treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibition agents |
| CN118043050A (zh) * | 2021-05-27 | 2024-05-14 | 迪斯克医药公司 | 用固体形式的比托哌汀治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154370A0 (en) | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| RS53252B (sr) * | 2003-08-11 | 2014-08-29 | F.Hoffmann-La Roche Ag. | Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1 |
| MX2009006859A (es) | 2006-12-28 | 2009-07-03 | Hoffmann La Roche | Formas cristalinas de glyt1. |
-
2007
- 2007-12-18 MX MX2009006859A patent/MX2009006859A/es active IP Right Grant
- 2007-12-18 HU HUE07857734A patent/HUE025032T2/en unknown
- 2007-12-18 JP JP2009543441A patent/JP4799666B2/ja active Active
- 2007-12-18 MY MYPI20092584A patent/MY188367A/en unknown
- 2007-12-18 RS RS20150229A patent/RS53910B1/sr unknown
- 2007-12-18 SI SI200731644T patent/SI2114405T1/sl unknown
- 2007-12-18 WO PCT/EP2007/064104 patent/WO2008080821A1/en not_active Ceased
- 2007-12-18 DK DK07857734T patent/DK2114405T3/en active
- 2007-12-18 HR HRP20150573TT patent/HRP20150573T1/hr unknown
- 2007-12-18 ES ES07857734.3T patent/ES2535040T3/es active Active
- 2007-12-18 CN CNA2007800479512A patent/CN101573114A/zh active Pending
- 2007-12-18 KR KR1020097015643A patent/KR101130146B1/ko active Active
- 2007-12-18 BR BRPI0720829A patent/BRPI0720829B8/pt active IP Right Grant
- 2007-12-18 UA UAA200907731A patent/UA100232C2/uk unknown
- 2007-12-18 RU RU2009124113/04A patent/RU2463295C2/ru active
- 2007-12-18 NZ NZ577502A patent/NZ577502A/en unknown
- 2007-12-18 EP EP07857734.3A patent/EP2114405B1/en active Active
- 2007-12-18 CA CA002673667A patent/CA2673667A1/en not_active Abandoned
- 2007-12-18 AU AU2007341356A patent/AU2007341356B2/en active Active
- 2007-12-18 PT PT78577343T patent/PT2114405E/pt unknown
- 2007-12-18 PL PL07857734T patent/PL2114405T3/pl unknown
- 2007-12-19 US US12/002,997 patent/US20080214561A1/en not_active Abandoned
- 2007-12-25 TW TW096150002A patent/TWI388552B/zh active
- 2007-12-27 AR ARP070105913A patent/AR064545A1/es not_active Application Discontinuation
- 2007-12-27 CL CL200703830A patent/CL2007003830A1/es unknown
-
2008
- 2008-01-02 PE PE2008000055A patent/PE20081556A1/es not_active Application Discontinuation
-
2009
- 2009-06-08 CR CR10846A patent/CR10846A/es unknown
- 2009-06-11 CO CO09061117A patent/CO6190613A2/es not_active Application Discontinuation
- 2009-06-19 NO NO20092358A patent/NO342150B1/no unknown
- 2009-06-24 ZA ZA200904423A patent/ZA200904423B/xx unknown
- 2009-06-26 EC EC2009009471A patent/ECSP099471A/es unknown
- 2009-06-29 MA MA32049A patent/MA31029B1/fr unknown
-
2010
- 2010-07-22 US US12/841,195 patent/US8039473B2/en not_active Expired - Fee Related
-
2011
- 2011-07-22 US US13/188,486 patent/US20110295007A1/en not_active Abandoned
-
2012
- 2012-06-13 US US13/495,093 patent/US20120309969A1/en not_active Abandoned
-
2013
- 2013-03-13 US US13/798,358 patent/US20130197225A1/en not_active Abandoned
-
2015
- 2015-05-20 CY CY20151100451T patent/CY1116350T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081556A1 (es) | Formas cristalinas de glyt1 | |
| CY1121583T1 (el) | Πολυμορφικες και ψευδοπολυμορφικες μορφες της φαρμακευτικης ενωσης nxl104 | |
| PE20060372A1 (es) | Forma cristalina de clorhidrato de (-)-(1r, 2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol | |
| AR063347A1 (es) | Formas cristalinas de docetaxel y proceso para su preparacion | |
| ECSP11011309A (es) | Nueva forma cristalina vi de la agomelatina, preparación y uso de la misma | |
| AR064809A1 (es) | Formas cristalinas | |
| AR112227A2 (es) | Sal de hemifumarato del ácido 1-(4-{1-[(e)-4-ciclohexil-3-trifluorometil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxílico, y otras formas cristalinas de la misma | |
| PE20071016A1 (es) | Formas cristalinas de n-(benzo[b]tien-3-ilmetil)-sulfamida | |
| MX347804B (es) | Formas solidas de (r)-1(2,2-difluorobenzo[d] [1,3]dioxol-5-il)-n-( 1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il) -1h-indol-5-il) ciclopropanocarboxamida. | |
| PE20060284A1 (es) | Formas polimorficas de 3-(4-amino-1-oxo-1,3-dihidro-soindol-2-il)-piperidin-2,6-diona | |
| AR054777A1 (es) | Modificaciones cristalinas de piraclostrobina | |
| PE20061009A1 (es) | Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparacion, y composiciones farmaceuticas que la contienen | |
| AR034259A1 (es) | Polimorfos de un analogo de epotilona, procesos para prepararlos y las composiciones farmaceuticas que los contienen | |
| NO20045037D0 (no) | Fremgangsmate for fremstilling av atorvastatin-kalsium i amorf form | |
| AR073298A1 (es) | Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv. | |
| CL2007002450A1 (es) | Forma polimorfica i del enantiomero levogiro o dextrogiro de modafinilo; su procedimiento de preparacion; y composicion farmaceutica que los comprende (divisional solicitud 2693-03). | |
| CR8529A (es) | Nueva forma cristalina v de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contiene | |
| MX2022015151A (es) | Procesos para preparar acido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo. | |
| AR080275A1 (es) | Formas solidas de un derivado de n-( fenilmetil) propanamida y procedimientos de preparacion | |
| UY30393A1 (es) | Derivados sustituidos de la 1-piperidin-1-il-1,3-dihidro-2h-benzimidazol-2-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones | |
| ECSP12011659A (es) | Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis | |
| AR078627A1 (es) | N-((1r,2s,5r)-5-terc-butilamino)-2-((s)-3-(7-terc-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, forma cristalina, procedimiento de preparacion, composiciones farmaceuticas que los comprenden y uso del mismo para tratar diabetes, obesidad, enfermedades alerg | |
| EP2660856A4 (en) | PROCESS FOR PRODUCING HEXAGONAL SEMICONDUCTOR PLATE CRYSTALS | |
| ES2650604T3 (es) | Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene | |
| AR051043A1 (es) | Forma cristalina de clorhidrato de (3-cian-1h-indol-7il)-[4-(4-fluorofenetil)-piperazin-1-il]-metanona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |